This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Adverse event reporting can be found at the bottom of the page
Information on how to access prescribing information and adverse event reporting can be found at the bottom of this page.
A Proud Heritage of Cancer Research
Pfizer has a proud heritage within oncology and we continue to work tirelessly in our pursuit to discover and develop innovative and accessible treatments for those living with cancer.1
2003
2010
2012
2013
2016
2017
2018
2019
2020
2022
References:
1. Pfizer data on file.
2. Cision PR Newswire. SUTENT® Receives European Approval for a New Indication in Progressive Pancreatic Neuroendocrine Tumors (NET). December 2010. Available at: https://www.prnewswire.com/news-releases/sutent-receives-european-approval-for-a-new-indication-in-progressive-pancreatic-neuroendocrine-tumors-net-111182379.html. Last accessed September 2023.
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-3863. November 2021